Goodrx Holdings Inc (GDRX)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $1.21B
Last updated: Nov 17, 2026 at 11:05 AM ET
Goodrx Holdings Inc (GDRX) Stock Forecast
Analysts expect Goodrx Holdings (GDRX) to earn $0.30 per share in the fiscal year ending Dec 31, 2026, on revenue of $798.48M. Of 14 analysts, 4 rate the stock Buy or Strong Buy, 8 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.93, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 29% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 7.1% |
| Buy | 3 | 21.4% |
| Hold | 8 | 57.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 2 | 14.3% |
- Consensus
- Hold
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 16.7% and revenue estimates rise 4.7%.
- Fiscal year ending Dec 31, 2026
- $0.30
- EPS consensus, revenue $798.48M
- Fiscal year ending Dec 31, 2027
- $0.35
- EPS consensus, revenue $836.21M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.30 | $0.29 to $0.34 | 11 | $798.48M | $790.69M to $802.40M | 13 |
| Dec 31, 2027 | $0.35 | $0.30 to $0.45 | 11 | $836.21M | $809.05M to $850.90M | 13 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.08 | $0.07 to $0.11 | 15 | $206.12M | $192.86M to $215.36M | 14 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 4 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 5 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 3.2% from $0.31.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.30 | $0.30 | $0.30 | $0.30 | $0.31 | -1.9% |
| Fiscal year ending Dec 31, 2027 | $0.35 | $0.35 | $0.35 | $0.36 | $0.36 | -1.5% |
Frequently Asked Questions About GDRX
What is the GDRX stock forecast?
Consensus analyst estimates put Goodrx Holdings's EPS at $0.30 for the fiscal year ending Dec 31, 2026, on revenue of $798.48M. The consensus rating from 14 analysts is Hold.
How do analysts rate GDRX stock?
Of 14 analysts covering Goodrx Holdings, 1 rates it Strong Buy, 3 Buy, 8 Hold, 0 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from GDRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.30, with estimates from $0.29 to $0.34 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.35, with estimates from $0.30 to $0.45 from 11 analysts.
What revenue do analysts expect from Goodrx Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $798.48M, with estimates from $790.69M to $802.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $836.21M, with estimates from $809.05M to $850.90M.
How many analysts cover GDRX?
14 analysts rate Goodrx Holdings stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
GDRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors